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Figure: Patient-reported outcomes pre-surgery and six months post-surgery.
Violin plots show the distribution of scores, median (solid line) and inter-
quartile range (dashed lines) are superimposed. Panel A shows changes in
polycystic liver disease questionnaire (PLD-Q) score. Panel B and C show
changes in the physical component scale (PCS) and mental component scale
(MCS) of the 12-Item Short Form Survey (SF-12) questionnaire. Panel D
shows changes in EuroQol-Visual Analogue Scale (EQ-VAS) score.
Conclusion: Combined partial hepatectomy and cyst fenestration is
effective in reducing symptom burden and substantially improved
quality of life in selected patients with highly symptomatic PLD.
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Background and aims: Portal vein thrombosis (PVT) is a well-
recognized complication of end-stage liver disease. However, current
literature is still inconclusive about its impact on the clinical course in
liver transplant candidates.
The aim of this study was to identify the prevalence of and the risk
factors for PVT, to assess the usefulness of anticoagulant therapy and
to determine the impact of thrombosis as well as anticoagulation on
postoperative outcomes, patient and graft survival.
Methods:Weperformed a single center retrospective cohort study in
an expert liver transplant unit. Patient receiving liver transplantation
between January 2006 and June 2016 were included. Relevant
demographic, clinical and outcome data were retrieved from the
medical records. For analysis, patients were stratified in two groups
according to presence of PVT. Univariate and multivariate logistic
regression analysis and survival analysis were performed.
Results: During the study period 390 adult patients underwent
orthotopic liver transplantation. In 40 patients (10, 26%) PVT was
diagnosed. In respectively 10 (2, 56%), 7 (1, 79%) and 23 (5, 9%)
patients, the thrombus was identified at time of evaluation for
transplantation, during waiting time and at time of transplantation.
Among the 37 (9, 49%) cases who still had PVT at the time of
transplantation, 20 (54, 05%) showed partial and 17 (45, 05%) showed
complete thrombosis. In a multivariate analysis, body mass index
(p = 0, 006; OR 1,1; 95% CI:1, 028-1,177), previous treatment of portal
hypertension (p = 0, 001; OR 3, 59; 95% CI:1, 681-7, 671) and a history
of encephalopathy (p = 0, 007; OR 2, 86; 95% CI = 1, 332-6, 142) were
independently associated with the occurrence of PVT. A beneficial
trend was present favouring the use of anticoagulation towards the
accomplishment of recanalization (n = 3/7 versus 0/9; p = 0, 062). In
the anticoagulated patients, only one mild bleeding episode (14, 3%)
occurred. Operation timewas increased (p = 0, 001) in patientswhere
the thrombus was discovered incidentally during surgery. Length of
stay was increased (p = 0, 012) in the presence of PVT. Patient and
graft survival rates were similar between the groups with and
without portal vein thrombosis after 5 year of follow-up. However, 1-
year patient survival was significantly lower (p = 0, 031) in patients
with PVT. Variables independently associated with the risk of 1-year
and overall patient mortality included respectively the presence of
portal vein thrombosis (p = 0, 032) and male gender (p = 0, 023).
Conclusion: PVT occurred in 10% of patients awaiting liver trans-
plantation and had a deleterious effect on one year survival after liver
transplantation. Anticoagulation is safe and showed a beneficial trend
on recanalization of PVT and on the one year survival rate.
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Background and aims: There are limited data about the optimal
strategy of cardiovascular (CV) risk assessment during liver trans-
plant (LT) candidateworkup.We aimed to evaluate CV risk profile and
its correlation with early post-LT cardiac events.
Method: We included 555 adult patients (pts) who consecutively
underwent a first LT for cirrhosis at our Centre between January 2013
and December 2017, with a graft from brain-dead donor. CV risk
factors (RF) were collected.
Pre-LT cardiac workup included electrocardiogram (ECG) and
echocardiography (ECHO). Non-invasive stress testing was per-
formed in pts with ≥ 1 CV RF. We recorded adverse cardiac events
within 30 days post-LT.
Results: 78.2% were male; median LT age 56 years (y) [interquartile,
IQR, 51-61]; median body mass index 25.3 kg/m2 [23.2-27.8]. 47.4%
affected by virus-related cirrhosis, 15.0% alcohol-induced, 11.5%
alcohol+virus, 7.6% immune mediated, 4.1% NASH, 1.3% genetic
haemochromatosis and 13.1% mixed etiology. Median time between
listing and LT: 66 days [28-150]. Median MELD at LT: 14 [9-19], and
55.5% affected by hepatocellular carcinoma.
CV RF: 21.3% 60-64 y-old age,11.7% ≥ 65 y; 8.8% bodymass index > 30
Kg/m2; 33.3% smoking abuse; 14.2% mellitus diabetes requiring
insulin; 6.8% hyperlipidemia; 20.7% arterial hypertension; 0.7%
ischemic heart disease (2 pts with coronary artery stent); 0.9%
stroke/ischemic attack; 0.2% dialysis, 0.9% creatinine > 2 mg/dL.
26.3% of the pts had 0 CVRF; 42.7% 1 RF,19.3% 2 RF, 8.8% 3 RF, 2.5% 4 RF
and 0.4% 5 RF.
ECG showed ischemic changes in 1.1% and chronic atrial fibrillation in
0.4% of the pts.
ECHO showed: 96.6% with ejection fraction ≥ 55% and 96.4% with
normal/stage 1 diastolic dysfunction.
44.7% of the pts underwent non-invasive stress testing (dobutamin/
dipyridamole ECHO or myocardial scintigraphy), which was positive
in 1.1% of the pts; all of them underwent coronary angiographywhich
did not show coronary disease.
2 pts underwent pre-LT transcatheter aortic valve replacement for
severe aortic stenosis.
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